000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c16836 _d16836 |
||
003 | PC16836 | ||
005 | 20220505131527.0 | ||
008 | 220505b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_91974 _aLombera Romero, Federico _eCardiología |
||
100 |
_93035 _aFernández, María S _eCardiología |
||
100 |
_9433 _aSepúlveda Sánchez, Juan Manuel _eOncología Médica |
||
245 | 0 | 0 |
_aCardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. _h[artículo] |
260 |
_bCardiovascular toxicology, _c2015 |
||
300 | _a15(4):309-23. | ||
500 | _aFormato Vancouver: Kovacs RJ, Maldonado G, Azaro A, Fernández MS, Romero FL, Sepulveda Sánchez JM et al. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23. | ||
501 | _aPMID: 25488804 PMCID: PMC4575352 | ||
504 | _aContiene 36 referencias | ||
520 | _aTransforming growth factor-beta (TGF-β) signaling plays an important role in the fetal development of cardiovascular organs and in the repair mechanisms of the heart. Hence, inhibitors of the TGF-β signaling pathway require a careful identification of a safe therapeutic window and a comprehensive monitoring of the cardiovascular system. Seventy-nine cancer patients (67 glioma and 12 solid tumor) enrolled in a first-in-human dose study and received the TGF-β inhibitor LY2157299 monohydrate (LY2157299) as monotherapy (n = 53) or in combination with lomustine (n = 26). All patients were monitored using 2D echocardiography/color and Spectral Doppler (2D Echo with Doppler) every 2 months, monthly electrocardiograms, thorax computer tomography scans every 6 months, and monthly serum brain natriuretic peptide (BNP), troponin I, cystatin C, high-sensitivity C-reactive protein (hs-CRP). Administration of LY2157299 was not associated with medically relevant cardiovascular toxicities, including patients treated ≥6 months (n = 13). There were no increases of troponin I, BNP, or hs-CRP or reduction in cystatin C levels, which may have been considered as signs of cardiovascular injury. Blood pressure was generally stable during treatment. Imaging with echocardiography/Doppler showed an increase in mitral and tricuspid valve regurgitation by two grades of severity in only one patient with no concurrent clinical symptoms of cardiovascular injury. Overall, this comprehensive cardiovascular monitoring for the TGF-β inhibitor LY2157299 did not detect medically relevant cardiac toxicity and hence supports the evaluation of LY2157299 in future clinical trials. | ||
710 |
_9119 _aServicio de Cardiología |
||
710 |
_9303 _aServicio de Oncología Médica |
||
856 |
_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575352/ _yAcceso libre |
||
942 |
_2ddc _cART _n0 |